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Abstract
Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL)/Apo-2L promotes apoptosis in
cancer cells while sparing normal cells. Although many cancers are sensitive to TRAIL-induced
apoptosis, some evade the proapoptotic effects of TRAIL. Therefore, differentiating molecular
mechanisms that distinguish between TRAIL-sensitive and TRAIL-resistant tumors are essential for
effective cancer therapies. Here, we show that c-Fos functions as a proapoptotic agent by repressing
the antiapoptotic molecule c-FLIP(L). c-Fos binds the c-FLIP(L) promoter, represses its
transcriptional activity, and reduces c-FLIP(L) mRNA and protein levels. Therefore, c-Fos is a key
regulator of c-FLIP(L), and activation of c-Fos determines whether a cancer cell will undergo cell
death after TRAIL treatment. Strategies to activate c-Fos or inhibit c-FLIP(L) may potentiate TRAIL-
based proapoptotic therapies.
Introduction
Aberrant apoptotic pathways contribute to initiation and progression of neoplasia; therefore,
proapoptotic agents can be used for treatment of various malignancies (1). Although many
cancers are sensitive to proapoptotic agents like tumor necrosis factor (TNF), FasL, and TNF-
related apoptosis-inducing ligand (TRAIL)/Apo-2L (2), some develop resistance and apoptotic
stimuli become ineffective (3). Whereas many apoptotic stimuli are associated with severe
systemic cytotoxicity, limiting their clinical utility, TRAIL/Apo-2L has the unique feature of
inducing apoptosis in cancer cells, with minimal cytotoxicity. Differentiating between cancers
that are sensitive to TRAIL-induced apoptosis and cancers that are resistant to TRAIL-induced
apoptosis can improve the efficacy of TRAIL-related compounds that are currently in clinical
trials (4).
TRAIL-induced apoptosis may involve both extrinsic and intrinsic pathways and can be
regulated by many important factors such as nuclear factor-κB (NF-κB), Akt, Bcl-2, Bax,
XIAP, IAPs, Smac/DIABLO, and c-FLIP (FLICE-like inhibitory protein; ref. 5). We
previously showed that expression of the antiapoptotic molecule c-FLIP(L) is necessary and
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sufficient to maintain resistance to TRAIL-induced apoptosis (4). Although expression of c-
FLIP(L) can be regulated at the translational and posttranslational levels, we have found that
expression of c-FLIP(L) can also be partially regulated at the transcriptional level. In this report,
we show that transcription of c-FLIP(L) is repressed by the c-Fos oncoprotein.
Fos proteins are basic region-leucine zipper (bZIP) transcription factors that bind to Jun or
other bZIP proteins and create the activator protein 1 (AP-1) dimer complex, which regulates
gene expression (6). c-Fos, a well-established oncogene, is considered to play a critical role in
tumorigenesis, proliferation and transformation, angiogenesis, tumor invasion, and metastasis,
and its expression is associated with poor clinical outcomes (6). Therefore, c-Fos has
preferentially been considered an antiapoptotic molecule. However, recent evidence suggests
that c-Fos may also have a proapoptotic role. The first indication of such proapoptotic function
of c-Fos comes from the observation that c-Fos expression preceded apoptosis (7), and is also
observed during mammary gland involution (8) and in other systems (9). However,
proapoptotic downstream molecular targets of c-Fos are poorly understood.
In this report, we show that c-Fos has a novel proapoptotic function in TRAIL-induced
apoptosis. We show that nuclear c-Fos primes cancer cells to undergo apoptosis, and its
expression is necessary but insufficient for TRAIL-induced apoptosis. Activation of c-Fos/
AP-1 is critical for cancer cells to undergo apoptosis after treatment with TRAIL/Apo-2L. We
show that c-Fos, as a pro-apoptotic molecule, represses the antiapoptotic gene, c-FLIP(L), by
direct binding to the promoter region of c-FLIP(L).
Materials and Methods
Materials
Horseradish peroxidase–conjugated secondary antibody (goat–anti-mouse, goat–anti-rabbit,
goat–anti-rat antibodies), biotinylated goat–anti-rabbit secondary antibodies, Oct-1 antibody,
c-Fos antibody (D1), c-FLIP antibody (G11), c-Jun antibody, Fos B antibody, Fra 1 antibody,
Fra 2 antibody, Jun B antibody, Jun D antibody, and c-Fos small interfering RNA (siRNA)
were obtained from Santa Cruz Biotechnology, Inc. c-Jun and c-Fos were obtained from Cell
Signaling Technology, Inc. Recombinant human TRAIL/TNFSF10 was obtained from R&D
Systems, Inc. Monoclonal anti-FLIP antibody (Dava II) was obtained from Apotech Corp. α-
Tubulin antibody was purchased from Sigma. Glyceraldehyde-3-phosphate dehydrogenase
antibody was from Abcam, Inc. γ-32P–labeled ATP was purchased from Perkin-Elmer.
Cell culture
PC3, LNCaP, A-498, 786-O, 769-P, MDA-MB231, and MDA-MB453 were obtained from the
American Type Culture Collection. PC3-TR is a TRAIL-resistant subline of PC3 cells (10).
SN12-PM6 was supplied by Dr. I.J. Fidler, M.D. Anderson Cancer Center (Houston, TX).
Cells were cultured as previously described (10).
Cell viability
Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) method (Roche Diagnostics) as previously described (10). Cells were then
treated with various concentrations of TRAIL.
Apoptosis assay
Apoptosis was detected by using fluorescein-conjugated Annexin V (Annexin V–FITC) kit
according to manufacturer’s protocol (BD Biosciences).
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Western blot analyses and immunofluorescence
Western blot and immunofluorescence experiments were carried out as previously described
(10,11). Nuclear extraction was prepared according to the kit from Pierce Biotechnology, Inc..
Oct-1 is used as loading control of nuclear extraction. If the Oct-1 amount of whole-cell lysate
is at 20% or less than that of the nuclear extraction, nuclear extraction is considered as qualified
extraction. Band density was analyzed by GelDoc (Bio-Rad Laboratories).
Luciferase assay
c-FLIP(L) promoter (−1,179 to +281) luciferase structure was provided by Dr. W.S. El-Deiry
(University of Pennsylvania, Philadelphia, PA; ref. 12). c-FLIP(L) promoter with the deletion
of AP-1-(f) site was prepared by our laboratory. Briefly, c-FLIP(L) promoter (−1,700, +300)
was cloned from Bac-IP11-536I18 (Children’s Hospital, Oakland Research Institute, Oakland,
CA) with appropriate primers for PCR amplification. The primers used were sense, 5′-
CTCGAGTGAACCTGG-GAGGTTAAGGC-3′; antisense, 5′-
AGATCTGAGGCAAAGAAACCGAAAGC-3′, which contained an XhoI site and BglII site,
respectively. The PCR products were inserted into pGEMT-Easy vector (Promega Co.). Once
the sequence of the construct had been verified, it was subcloned into the PGL3-enhancer vector
(Promega) at XhoI and BglII sites. AP-1-(f) site binding site was deleted from the above c-
FLIP(L)/PGL3-enhancer construct by QuikChange II XL Site-Directed Mutagenesis Kit
(Stratagene). The primers used were as follows: sense, 5′-
GAGGCCGAGGCGGGCAAGGACCAG-CAGTTGGAGACCAGCC-3′; antisense, 5′-
GGCTGGTCTCCAACTGCTGGT-CCTTGCCCGCCTCGGCCTC-3′. The sequence of
“TCACTTGAGG” was deleted and verified by DNA sequencing. Cells were seeded into 24-
well plates. When cells reached 80% confluence, both AP-1 luciferase reporter (25 ng/well)
and Renilla reporter (5 ng/well) from Stratagene or c-FLIP(L) reporter and Renilla reporter
were cotransfected into cells. In other experiments, when cell reached 70% confluence, c-Fos
siRNA, c-Fos, or A-Fos were transfected into cells for 24 h before transfection of luciferase
and Renilla. Here, Renilla served as an internal control for transfection efficiency. After 24 h
of transfection, cells were treated with TRAIL (100 ng/mL), and then both attached and floating
cells were collected, prepared, and further detected by using Dual-Luciferase Reporter Assay
System (Promega). Samples were stored at −20°C until detection. All results represent average
of at least three independent experiments ± SD.
Cell extracts and electrophoretic mobility shift assay
Frozen cell pellets were resuspended as described (13). The reactions were made using 10 μg
of whole-cell extract and 0.1 to 0.5 ng of 32P-labeled double-stranded specific oligonucleotides
(5,000–25,000 cpm) in the presence of 2 μg of poly(deoxyinosinic-deoxycytidylic acid)
(Sigma) in binding buffer [25 mmol/L Tris (pH 8.0); 50 mmol/L KCl; 6 mmol/L MgCl2; 10%
v/v glycerol]. The reaction was incubated at room temperature for 20 min and run on 5% to
7% polyacrylamide 0.5× Tris glycine EDTA. Gels were dried with Bio-Rad gel dryer and
imaged using Kodak BioMax MR Film (Fisher Scientific). General AP-1 gel shift
oligonucleotide was obtained from Santa Cruz Biotechnology. Wild-type and mutant
oligonucleotides with four-tandem repeats of the c-FLIP(L) AP-1(f) site were designed as 5′-
ATCACTTGAGGATCACTTGAGGATCACTTGAGGATCACTTGAGG-3′ (wild-type) and
5′-ATTG CTTGAGGATTG CTTGAGGATTGCTTGAG-AGGATTGCTTGAGG-3′
(mutant). “Co” stands for competing control, using 90% cold prober plus 10% hot prober.
Transfection of c-Fos, A-Fos, and siRNA
Full-length human c-Fos cDNA was provided by Dr. L Shenshedini, University of Toledo,
Toledo, OH (14). A-Fos vector was obtained from Dr. Charles Vinson (National Cancer
Institute, Bethesda, MD; ref. 15). The plasmids with or without c-Fos or A-Fos were transfected
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with LipofectAMINE 2000 (Invitrogen Life Technologies). siRNA of c-Fos was transfected
into cells by TransMessenger (Qiagen). Nonspecific siRNA was used as control (Qiagen). After
transfection with the c-Fos or A-Fos vector for 24 h or c-Fos siRNA for 36 h, the cells were
seeded in 96-well plates for cell viability assays or treated with TRAIL.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assay was done by the ChIP Assay Kit (Upstate Cell
Signaling Solutions). Cells were cultured in 10-cm dishes, treated with or without TRAIL for
4 h. Cross-linking of DNA and proteins was carried out by adding formaldehyde for final
concentration of 1% and incubated for 10 min at 37°C. Both attached and floating cells were
collected, washed, and resuspended in 200 μL of SDS lysis buffer for 10 min and then sonicated.
Samples were centrifuged for 10 min at 13,000 rpm at 4°C and the supernatant was harvested.
Concentration of each sample was quantitated using BCA protein assay. Positive controls were
10% of each DNA sample, which did not included the immunoprecipitation step. The
remainder of the samples was equally divided into two groups. The experimental group was
immunoprecipitated with specific c-Fos (D-1) antibody, whereas the negative control group
was immunoprecipitated with general mouse IgG antibody. After immunoprecipitation,
protein-DNA cross-linking was reversed. The isolated DNA was first purified, then amplified
by PCR, using specific primers encompassing the c-FLIP(L) AP-1(f) binding site (Genbank).
The primers for the experiments in Fig. 4A are 5′-CCTGTGATCCCAG-CACTTTG-3′
(forward primer) and 5′-CACCATGCCCGACTAATTTT-3′ (reverse primer).
Xenograft orthotopic implantations and immunohistochemical analysis
Prostate and renal orthotopic implantations were carried out by injection of 1 × 106 cells in
either the posterolateral lobe of the prostate or beneath the kidney capsule of athymic nude
mice (Charles River Laboratories) at 6 to 8 weeks of age. Mice were implanted with the
following cells (untreated group/treated group): PC3 (six of five), PC3-TR (seven of five),
LNCaP cells (five of six), SN12-PM6 (eight of eleven), and A-498 (nine of eleven). After
implantation of the xenografts 10 weeks for prostate cancer cells and 3 weeks for renal cancer
cells, the athymic nude mice were randomly divided into treated and untreated groups and
treated with Lexatumumab (TRAIL receptor 2 agonist; Human Genome Science, Inc.) via tail
vein twice a week (10 mg/kg), as previously described (16). Four weeks after treatment, all
animals were euthanized and xenografts were harvested, and assessed for tumor weight,
metastasis, apoptosis, and immunoreactivity for c-Fos and c-FLIP. Tumor tissues were fixed
in 10% formalin and embedded in paraffin routinely. Histologic tests and
immunohistochemistry were carried out as previously described (11). The dilution of both c-
Fos (D1) and c-FLIP (G11) is 1:80. The mice were housed and maintained in laminar flow
cabinets under specific pathogen-free conditions. All experiments were approved by the
Institutional Animal Care and Use Committee at Beth Israel Deaconess Medical Center.
Terminal deoxynucleotidyl transferase-mediated nick end labeling
Terminal deoxyribonucleotide transferase–mediated nick-end labeling (TUNEL) was done to
assess the apoptotic cells using a commercial kit according to the manufacturer’s instruction
(Promega). Background reactivity was determined by processing slides in the absence of
terminal deoxynucleotidyl transferase (negative control); maximum reactivity was observed
by preincubating the tissue sections with DNase I to confirm the quality of the specimen and
availability of protocol. Tissue sections were mounted with Vectashield mounting medium
with 4′,6-diamidino-2-phenyl-indole (Vector Laboratories, Inc.) to counterstain the nuclei. At
least 200 cells from each sample were captured with a Nikon TE300 microscope and analyzed
by counting positive rate. Positive apoptotic rate is defied as the ratio of green staining within
nuclear area to the total nuclear staining (blue).
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Results
AP-1 activity is increased in TRAIL-sensitive cancer cells and c-Fos translocates to the
nucleus
Prostate cancer cells have variable sensitivity to recombinant human TRAIL/Apo-2L. We
found that PC3 cells were very sensitive to TRAIL/Apo-2L, whereas PC3-TR and LNCaP cells
were very resistant to TRAIL/Apo-2L (Fig. 1A). Previously, we have shown that c-FLIP(L),
but not c-FLIP(s), is necessary and sufficient to maintain resistance to TRAIL/Apo-2L (4). We
also found that expression of c-FLIP(L) is partially regulated at the transcriptional level. To
explore the transcription factors that regulate c-FLIP(L) and may play an important role in
differentiating between TRAIL-sensitive and TRAIL-resistant cancer cells, we analyzed the
putative promotor and regulatory regions of c-FLIP(L) by using the Alibaba 2.1 software
(17). We analyzed the possible transcription factor binding sites that spanned 17,000 bp of the
c-FLIP(L) gene, including 3 kb upstream of exon1, introns 1 to 2, and exon 2 region before
the ATG start codon (Fig. 1B). We identified potential binding sites for NF-κB (18,19),
androgen response elements (20) and Myc (12), all of which have been shown to regulate
expression of c-FLIP(L). In addition to identifying known transcription factors that regulate
c-FILP(L), we also found multiple potential AP-1 binding sites in the c-FLIP(L) regulatory
region (Fig. 1B). Because AP-1 family of proteins are important transcription factors, we
hypothesized that AP-1 might be an important regulator of c-FLIP(L); it may play a key role
in mediating cell response to TRAIL-induced apoptosis.
To determine whether AP-1 has any direct transcriptional activity in regulating TRAIL-induced
apoptosis, we examined for AP-1 activity and DNA binding in TRAIL-sensitive (PC3) and
TRAIL-resistant (PC3-TR and LNCaP) cells. We found that the activity of AP-1 significantly
increased in the TRAIL-sensitive PC3 cells; however, AP-1 activity did not significantly
change in the TRAIL-resistant PC3-TR and LNCaP cells (Fig. 1C). However, the increased
AP-1 activity in the TRAIL-sensitive cells were temporal; 24 h after TRAIL treatment, no more
AP-1 activity was detected because majority of the cells have undergone apoptosis by this time
(Fig. 1C; ref. 4). In addition, in the TRAIL-sensitive PC3 cells, we found increased AP-1 DNA
binding as determined by electrophoretic mobility gel shift assay (EMSA), a finding that was
not observed in the TRAIL-resistant PC3-TR or LNCaP cells (data not shown). These results
show that there is increased AP-1 activity and DNA binding in the TRAIL-sensitive cells, but
not in the TRAIL-resistant cells.
Because AP-1 family of proteins is composed of dimers between several family members, we
wished to determine which member(s) were mainly responsible for the increased AP-1 activity
in the TRAIL-sensitive PC3 cells after TRAIL treatment. Total protein whole-cell lysate
Western blot analysis did not reveal any differences in protein levels of the two major
components of AP-1, c-Fos and c-Jun (Fig. 1D, top), and other AP-1 family members (Fos B,
Jun B, Jun D, Fra1, and Fra2; data not shown) in either TRAIL-sensitive (PC3) or TRAIL-
resistant (PC3 and LNCaP) cancer cells after TRAIL/Apo-2L treatment. Because AP-1 is a
well-known transcription factor, we examined the nuclear levels of its different family member
proteins. Surprisingly, we found that expression of nuclear c-Fos was increased rapidly in the
TRAIL-sensitive PC3 cells by Western blot (Fig. 1D, bottom) and immunofluorescence
(Supplementary Fig. S1). In contrast, in TRAIL-resistant cells, we found that nuclear c-Fos
had either no significant change in PC3-TR cells or was deceased in LNCaP cells (Fig. 1D,
bottom). Nuclear c-Fos was increased in the PC3 cells after 10 min of TRAIL/Apo-2L treatment
and reached its peak after 4 h; however, nuclear c-Fos levels decreased at 24 h after treatment
because majority of PC3 cells were dead at this time point. In addition, there was no increase
in other nuclear AP-1 member proteins, including c-Jun, Fos B, Jun B, Jun D, Fra1, and Fra2
in the TRAIL-sensitive PC3 cells (Fig. 1D and data not shown). Therefore, the change in
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nuclear c-Fos protein levels (Fig. 1D) correlated with AP-1 activity levels (Fig. 1C) in the
TRAIL-sensitive PC3 cells.
Although c-Fos nuclear translocation occurred rapidly 10 min after TRAIL treatment in the
TRAIL-sensitive PC3 cells, we found that the TRAIL-sensitive PC3 cells undergo apoptosis
60 min after TRAIL treatment as determined by Annexin V-FITC flow cytometric assay (data
not shown). Therefore, c-Fos nuclear translocation may precede initiation of apoptosis in the
TRAIL-sensitive cells, and is maintained after they have undergone apoptosis.
To assure that the increased nuclear c-Fos we observed was not a PC3 cell line or prostate
cancer–specific phenomenon, we evaluated other TRAIL-sensitive and TRAIL-resistant renal
and breast cancer cells. We found that expression of nuclear c-Fos was also increased before
initiation of apoptosis in the TRAIL-sensitive renal (A-498) and breast (MDA-MB231) cancer
cells, but not in the TRAIL-resistant renal 786-O and breast cancer cells MDA-MB453 (data
not shown). Therefore, elevated nuclear c-Fos seems to occur before the cells undergo
apoptosis, and it is a common finding in different cancer cell types sensitive to TRAIL-induced
apoptosis.
c-Fos “primes” cancer cells to undergo apoptosis
We found that increased expression of nuclear c-Fos in the TRAIL-sensitive PC3 cells
correlated with increased AP-1 luciferase activity. However, it is unclear if increased c-Fos/
AP-1 merely reflects a stress response (21), or if activated c-Fos has a direct role in regulating
apoptosis. Silencing expression of nuclear c-Fos by siRNA reduced AP-1 activity (Fig. 2A)
and changed PC3 cells from TRAIL-sensitive to a more TRAIL-resistant phenotype (Fig.
2B). In addition, ectopic expression of a dominant-negative form of AP-1, A-Fos (15), also
reduced the AP-1 activity in the PC-3 cells (Fig. 2C), and converted the PC3 cells from a
TRAIL-sensitive to a TRAIL-resistant phenotype (Fig. 2D). These data show that c-Fos primes
cancer cells to undergo cell death, and nuclear localization of c-Fos is necessary for TRAIL-
induced apoptosis.
c-Fos represses the expression of c-FLIP(L) directly
c-Fos/AP-1 increases in the TRAIL-sensitive PC3 cells after TRAIL/Apo-2L treatment (Fig.
1C and D), whereas previously we have found that c-FLIP(L) expression in PC3 cells decreases
in a time- and dose-dependent manner after TRAIL/Apo-2L treatment (4). The inverse
correlation between c-Fos and c-FLIP(L) protein levels in the TRAIL-sensitive cells, and the
presence of multiple AP-1 binding sites in c-FLIP(L) regulatory region (Fig. 1B), prompted us
to examine whether the c-Fos/AP-1 in TRAIL-sensitive cells may affect the expression of the
antiapoptotic molecule, c-FLIP(L). After treatment with TRAIL/Apo-2L, c-FLIP(L) promoter
luciferase activity was reduced in the TRAIL-sensitive PC3 cells, whereas c-FLIP(L) promoter
luciferase activity was potentiated in the TRAIL-resistant PC3-TR and LNCaP cells (Fig.
3A). The reduced c-FLIP(L) luciferase activity correlated with reduced c-FLIP(L) mRNA and
protein levels in the TRAIL-sensitive PC3 cells. However, c-FLIP(L) mRNA and protein levels
in the TRAIL-resistant PC3-TR and LNCaP cells were unchanged before and after TRAIL
treatment (Fig. 3B). Silencing expression of c-Fos by siRNA potentiated the c-FLIP(L)
promoter luciferase activity after treatment with TRAIL/Apo-2L in the TRAIL-sensitive PC3
cells, whereas the c-FLIP(L) promoter luciferase activity was reduced when c-Fos expression
was not silenced (Fig. 3C). Moreover, protein levels of c-FLIP(L) were maintained when c-
Fos expression was either reduced by siRNA (Figs. 2A and 3D) or its AP-1 activity was
suppressed by a AP-1 dominant-negative A-Fos (Figs. 2C and 3D).
To further determine whether c-Fos has any direct transcriptional activity in regulating c-FLIP
(L), we examined the potential AP-1 binding sites in the putative c-FLIP(L) regulatory region
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[17,000 bp upstream of the c-FLIP(L) ATG start codon; Fig. 1B]. We identified and examined
binding of c-Fos to 14 AP-1 binding sites in the putative c-FLIP(L) regulatory region via ChIP
assays, which included six AP-1 binding sites before exon 1 (designated sites “a” through “f”
in Fig. 1B) and eight within introns 1 to 2. We only detected binding of c-Fos protein to the c-
FLIP(L) AP-1(f) site (Figs. 1B and 4A). ChIP assays showed that binding of c-Fos to the c-
FLIP(L) AP-1(f) site increased in the TRAIL-sensitive PC3 cells, whereas c-Fos binding to
the c-FLIP(L) AP-1(f) site was reduced in the TRAIL-resistant PC3-TR and LNCaP cells after
treatment with TRAIL/Apo-2L. To confirm the importance of c-Fos/AP-1 binding AP-1(f) site
on regulating c-FLIP(L) expression, we deleted this AP-1(f) site in our c-FLIP(L) promoter
luciferase reporter. We found that deletion of the c-FLIP(L) AP-1(f) site abolished the ability
of c-Fos to suppress c-FLIP(L) expression (Fig. 4B). To further determine whether AP-1
binding to the c-FLIP(L) AP-1(f) site was specific to this AP-1(f) DNA sequence, we designed
a wild-type and mutant oligonucleotide with four-tandem repeats of the AP-1(f) binding site.
EMSA showed that binding to the wild-type AP-1(f) sequence was increased in the TRAIL-
sensitive PC3 cells after treatment with TRAIL/Apo-2L, whereas there was minimal to no
binding to the wild-type AP-1(f) site in the TRAIL-resistant PC3-TR and LNCaP cells (Fig.
4C). In contrast, binding to the mutant AP-1(f) site was abolished, regardless of whether the
cells were TRAIL-sensitive or TRAIL-resistant. These data further confirm that c-Fos protein
binds to c-FLIP(L) AP-1(f) site, represses expression of c-FLIP(L) gene, and sensitizes cancer
cells to undergo TRAIL-induced apoptosis. Deletion and mutations of the c-FLIP(L) AP-1(f)
promoter region abrogates the ability of c-Fos to repress the antiapoptotic molecule, c-FLIP
(L).
Ectopic expression of c-Fos represses c-FLIP(L) and sensitizes TRAIL-resistant cancer cells
Next, we wished to determine whether ectopic expression of c-Fos can alter TRAIL-induced
apoptosis in resistant prostate cancer cells. c-Fos was ectopically expressed in TRAIL-resistant
PC3-TR and LNCaP cells. Concomitant with increased c-Fos protein levels in both PC3-TR
and LNCaP cells, c-FLIP(L) levels were reduced by half (Fig. 5A), AP-1 activity was increased
(Fig. 5B), and cell viability was decreased (Fig. 5C). These data suggest that c-Fos represses
the expression of the antiapoptotic molecule, c-FLIP(L). In addition, ectopic expression of
wild-type c-Fos in PC3-TR and LNCaP cells was associated with increased c-Fos protein levels
and enhanced AP-1 activity, which led to nuclear localization of c-Fos (data not shown), but
did not promote cell death (Fig. 5C). Therefore, the TRAIL-resistant cells (LNCaP and PC3-
TR) were sensitized to TRAIL when c-Fos was ectopically expressed. We conclude that nuclear
localization of c-Fos by itself is necessary but insufficient to promote apoptosis in cancer cells.
c-Fos translocates to the nucleus in orthotopic in vivo xenografts
To determine whether nuclear expression of c-Fos that we observed in vitro in the TRAIL-
sensitive cancer cells is also found in in vivo models, we orthotopically implanted prostate
cancer cells (PC3, PC3-TR, and LNCaP) and renal cancer cells (SN12-PM6, A-498) in the
posterolateral lobe of the prostate and under the kidney capsule of athymic nude mice,
respectively. After orthotopic implantation of the xenografts (11), the athymic mice were
treated with a TRAIL receptor 2 agonist antibody (Lexatumumab), which is currently in clinical
trials for advanced malignancies (4). Lexatumumab has equivalent sensitivity and resistance
profiles and induces similar downstream signaling molecules as recombinant TRAIL (16).
Orthotopically implanted xenografts were treated for 4 weeks with i.v. Lexatumumab, and
primary tumors were harvested and assessed for tumor weight, TUNEL staining, and
expression of c-Fos and c-FLIP(L). The rate of tumor formation in the TRAIL-sensitive and
TRAIL-resistant xenografts was equivalent, and there was no significant difference in the body
weight of the animals in the treated and untreated groups (Supplementary Table S1). However,
TRAIL-sensitive xenografts had a much higher apoptotic rate (P < 0.01) and significantly
decreased tumor burden (P < 0.05) when the animals were treated with Lexatumumab
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compared with the control groups. In contrast, the apoptotic rates were very low and there was
no significant difference of tumor burden in TRAIL-resistant PC3-TR and LNCaP xenografts
with or without treatment (Supplementary Table S1). Similar results were also observed in
renal cancer SN12-PM6 and A-498 xenografts (22). Next, we found that expression of nuclear
c-Fos was pronounced in the TRAIL-sensitive PC3, SN12-PM6, and A-498 xenografts after
treatment, but not in the TRAIL-resistant PC3-TR and LNCaP xenografts (Fig. 6). These
findings suggest that increased nuclear expression of c-Fos is found not only in TRAIL-
sensitive in vitro models, but also in orthotopic in vivo models after treatment with TRAIL
receptor agonist compounds. Potentially, nuclear localization of c-Fos could be used to identify
human cancers that are sensitive to TRAIL-induced apoptosis.
Discussion
Because the AP-1 family member protein c-Fos plays a crucial role in a variety of biological
processes, identifying the downstream targets of c-Fos has significant implications in
understanding of normal development, inflammation, and oncogenesis (6). In this report, we
show that c-Fos, in addition to its well-known oncogenic function, has a novel proapoptotic
function in TRAIL-induced apoptosis. c-Fos exerts its proapoptotic function by repressing c-
FLIP(L). We define Fos-dependent priming (FDP) as increased expression of nuclear c-Fos
after treatment with TRAIL/Apo-2L. Clinical implications of these results include the
possibility of using FDP as a marker in cancer patients being treated with proapoptotic agents.
The presence of FDP may identify tumors that are sensitive to proapoptotic stimuli, whereas
lack of FDP identifies resistant tumors.
Caspases are important modulators of apoptosis (for review, see ref. 23). Activation of specific
death domain receptors, like DR4 and DR5 by their ligand, TRAIL, promotes formation of
death-inducing signaling complex (DISC). DISC recruits an adaptor molecule, Fas-associated
death domain (FADD), which in turn interacts with and activates caspase-8 and/or caspase-10,
leading to initiation of the extrinsic proapoptotic signaling pathway. Because of its sequence
homology with caspase-8, c-FLIP(L) has been shown to competitively inhibit the interaction
between FADD and caspase-8, and thus inhibits the initiation of proapoptotic stimuli. We and
others (4,24,25) have shown that persistent expression of c-FLIP(L) is necessary and sufficient
to maintain resistance to TRAIL-induced apoptosis. Here, we show that c-Fos represses
expression of c-FLIP(L). Therefore, for a cancer cell to undergo apoptosis after TRAIL
treatment is dependent on a feedback loop mechanism as determined by activation of c-Fos
and c-FLIP(L) level.
c-Fos is one of the immediate-early response and inducible transcription factors. Its level is
increased after many stress stimuli, including some proapoptotic stimuli. For example, c-Fos
levels have been increased after chemotherapy (26), UV radiation (27,28), and TNF-α exposure
(29). Few studies have noted increased levels of c-Fos after TRAIL treatment (30,31); however,
the function of c-Fos in these biological settings have not been clearly defined. Although, c-
Fos usually acts as a transcriptional activator, it has been shown that it can also function as a
transcriptional suppressor. For example, c-Fos can negatively regulate its own expression
(32,33), or other molecules like inducible nitric oxide synthase, TNF-α, and IL-12 (34,35). Our
report shows for the first time the role of c-Fos as a repressor of the antiapoptotic molecule, c-
FLIP(L).
We postulate that posttranslational modifications of c-Fos may determine whether cancer cells
are sensitive or resistant to TRAIL-induced apoptosis. In our in vitro and orthotopic in vivo
studies, we showed that nuclear translocation of c-Fos and repression of c-FLIP(L) gene is an
important process in promoting TRAIL-induced apoptosis in cancer cells. Cellular localization
and activation of c-Fos can depend on its phosphorylation, protein stability, and other
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chaperone proteins. Recent work has suggested that phosphorylation of c-Fos, which is an
important determinant of its activity and expression, is tightly regulated by a variety of kinases
such as mitogen-activated protein kinase (36), FRK (37), RSK2 (38), CKII (39), and PDK1
(40). Protein stability of c-Fos, another regulator of its physiologic function, has been shown
to be dependent on its COOH-terminal PEST3 domain, which modulates c-Fos proteosome-
mediated degradation (41). Associated proteins in the form of chaperone proteins or
heterodimers can also regulate c-Fos structure and function. As a follow-up study to the current
report, we have recently reported that the proteosome inhibitor, MG-132, sensitizes TRAIL-
resistant cancer cells by up-regulating AP-1 activity (22). Therefore, up-regulation of AP-1
and sensitization to TRAIL-induced apoptosis is another example of necessary mechanisms
that may serve an important function in overcoming resistance to TRAIL-induced apoptosis.
Therefore, we believe that the posttranslational modifications of c-Fos can significantly affect
its ability to regulate c-FLIP(L) gene expression and TRAIL-induced apoptosis, and it is an
area under investigation in our laboratory.
The c-FLIP family of proteins is homologous to pro-caspase-8 (for review, see ref. 23). Both
c-FLIP(L) and c-FLIP(s), and perhaps the newly detected c-FLIP(r) (42), can bind to the DED
domains of FADD and caspase-8 and regulate apoptosis through their interference with the
recruitment of caspase-8 to FADD. Most reports suggest that c-FLIP(L) has an anti apoptotic
role, largely due to results from experiments using ectopic expression of c-FLIP(L). Moreover,
c-FLIP(L)−/− mouse embryonic fibroblasts are more sensitive to proapoptotic agents, which
strongly suggests that c-FLIP(L) has an antiapoptotic function (43). However, some recent
reports suggest that c-FLIP(L) may have a dual function, a proapoptotic function at low
physiologic concentrations, and an antiapoptotic function at high cellular concentrations (44).
In accordance with the role of c-FLIP(L) as an antiapoptotic molecule, we have found that
persistent expression of c-FLIP(L) is necessary and sufficient to maintain resistance to TRAIL-
induced apoptosis. Meanwhile, our observations found that level of c-FLIPs were too low to
be detected by Western blot in prostate and renal cancer cell lines we used, which did not
support that c-FLIPs might play an important role in regulating TRAIL sensitivity in these
cells. Although regulation of c-FLIP(L) can occur at the translational and posttranslational
levels, we found that transcriptional regulation of c-FLIP(L) may also affect cancer cell
sensitivity to TRAIL-induced apoptosis (10). Other investigators have shown that NF-κB
(18,19), c-Myc (12), nuclear factor of activated T cells (45), and even androgen receptor
response elements (20) may regulate expression of c-FLIP(L) through direct or indirect
mechanisms. Here, we show that c-Fos directly binds the AP-1(f) site of the c-FLIP(L) gene
(Fig. 4A), represses expression of c-FLIP(L), and promotes TRAIL-induced apoptosis. In
contrast, deletion of the AP-1(f) site abrogates binding of c-Fos, leading to enhancement of c-
FLIP(L) gene expression and resistance to TRAIL-induced apoptosis. The AP-1(f) site lies
within a CpG island (Fig. 1B); therefore, methylation patterns in this site may regulate the
direct interaction between c-Fos protein and the c-FLIP(L) gene.
Some limitations of our study is that we only investigated the effect of c-Fos/AP-1 on c-FLIP
(L). It is likely that c-Fos regulates other apoptosis-related molecules besides c-FLIP(L) to alter
cell sensitivity to TRAIL-induced apoptosis. Our rationale for investigating the interaction
between c-Fos and c-FLIP(L) stems from prior reports demonstrating up-regulation of c-Fos
in cancer cells after TRAIL treatment (30,31), presence of multiple c-Fos/AP-1 binding sites
in the putative promoter region of c-FLIP(L) (Fig. 1B), and our previous work suggesting that
c-FLIP(L) could be regulated transcriptionally in cancer cells after TRAIL treatment (10). In
addition, we have not investigated the mechanism that c-Fos is translocated from the cytoplasm
to the nucleus. Chaperon proteins, alterations in c-Fos phosphorylation, or changes in c-Fos
protein stability are all potential mechanism that may play a role in translocation of c-Fos from
the cytoplasm to the nucleus in TRAIL-sensitive cells. Currently, these areas are under active
investigation in our laboratory.
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In conclusion, we have shown that c-Fos has a proapoptotic function by repressing the
antiapoptotic molecule, c-FLIP(L). FDP is necessary but insufficient for TRAIL-induced
apoptosis. We believe that presence of FDP identifies cancers that are sensitive, while lack of
FDP identifies cancers that are resistant to TRAIL-induced apoptosis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Nuclear c-Fos and AP-1 are up-regulated in TRAIL-sensitive cancer cells after TRAIL
treatment. A, cells were treated with TRAIL/Apo-2L with different doses for 24 h and assayed
for death by the MTT assay. [A is the same as the one used in our prior work (10); it is only
shown here to demonstrate to the current readers our model of TRAIL-sensitive and TRAIL-
resistant prostate cancer cells]. B, potential binding sites for putative transcriptional factors in
the cFLIP(L) promoter and regulatory region. Putative AP-1, NF- κB, and ARE sites are
indicated. C, time course of AP-1 luciferase activity after TRAIL/Apo-2L in prostate cancer
cells. D, c-Fos and c-Jun whole-cell lysate (top) and nuclear (bottom) protein levels after
TRAIL treatment at different time points. Oct-1 is used as loading control for nuclear extracts.
Bars, SD from at least three independent experiments.
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Figure 2.
Inhibition of c-Fos/AP-1 converts TRAIL-sensitive PC3 cells to a more TRAIL-resistant
phenotype. A, nuclear c-Fos protein levels and AP-1 luciferase activity in PC3 cells after using
c-Fos siRNA in the absence or presence of TRAIL. Oct-1 is loading control for nuclear extracts.
B, cell viability assays, with control nonspecific siRNA (−) or with c-Fos siRNA (+), before
and after TRAIL treatment. C, AP-1 luciferase activity and protein expression of c-Fos/A-Fos
transfection of dominant-negative AP-1, A-Fos, and TRAIL treatment. Note that c-Fos
antibody recognizes both A-Fos and c-Fos. D, cell viability assays with A-Fos ectopic
expression. *, significant differences between control and experimental samples. B, SD of at
least three replicate experiments. c-Fos transfection (−) or A-Fos transfection (−) refer to empty
vector control transfections.
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Figure 3.
c-Fos represses expression of c-FLIP(L). A, fold change in luciferase activity of c-FLIP(L)
promoter region. B, mRNA and protein levels of c-FLIP(L) in PC3, PC3-TR, and LNCaP cells
after TRAIL treatment at various time points. C, relative change in luciferase activity of c-
FLIP(L) promoter region in the absence or presence of c-Fos siRNA and treatment with TRAIL.
D, expression of c-FLIP(L) protein in the absence or presence of c-Fos siRNA or dominant
negative AP-1 (A-Fos). * and #, statistically significant difference between control and
experimental samples. Bars, SD of at least three replicate experiments.
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Figure 4.
c-Fos represses expression of c-FLIP(L) by direct binding to its promoter region. A, AP-1(f)
binding to c-FLIP(L) promoter analyzed by CHIP assay. Cells were treated with TRAIL (100
ng/mL) for 4 h. B, c-FLIP(L) promoter luciferase activity after deletion of AP-1(f) in the
presence and absence of TRAIL/Apo-2L. Wt and Del, wild-type c-FLIP(L) promoter luciferase
reporter and deletion of AP-1(f) site from the reporter, respectively. C, EMSA of AP-1 using
a wild-type or mutated four-tandem oligonucleotide of the c-FLIP(L) AP-1(f) binding site as
probes. Co, competing control. *, statistically significant difference between indicated groups.
Bars, SD of at least three replicate experiments.
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Figure 5.
Ectopic expression of c-Fos sensitizes TRAIL-resistant PC3-TR and LNCaP cells. A,
expression of c-Fos and c-FLIP(L) in PC3-TR and LNCaP cells in the absence or presence of
c-Fos transfection. Numbers, band intensity. AP-1 luciferase activity (B) and cell viability
(C) of PC3-TR and LNCaP cells with empty vector (−) or with c-Fos (+) ectopic expression,
and treatment with TRAIL. *, significant difference between indicated groups. Bars, SD of at
least three replicate experiments.
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Figure 6.
Immunohistochemical analysis of orthotopically implanted prostate cancer cells (PC3, PC3-
TR, and LNCaP) and renal cancer cells (SN12-PM6 and A-498). Representative
immunohistochemical images of c-Fos without (−) or with (+) Lexatumumab treatment in
TRAIL-sensitive or TRAIL-resistant prostate cancer and renal cancer xenografts. Bar, ~50
μm.
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